The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Why not treat human cancer with interleukin-1 blockade?
Open accessAbstract
The clinical successes of targeting angiogenesis provide a basis for trials of interleukin-1 (IL-1) blockade and particularly anti-IL-1beta as an add-on therapy in human metastatic disease. In animal studies for over 20 years, IL-1 has been demonstrated to increase adherence of tumor cells to the endothelium in vitro, and administration of IL-1 to mice increases the number of metastatic colonies and tumor growth. Importantly, reducing endogenous IL-1 activity, particularly IL-1beta, with the naturally occurring IL-1 receptor antagonist (IL-1Ra) reduces both metastasis as well as tumor burden. Inhibition of IL-1 activity prevents in vivo blood vessel formation induced by products released from hypoxic macrophages or vascular endothelial cell growth factor itself. Mice deficient in IL-1beta do not form blood vessels in matrigels embedded with vascular endothelial cell growth factor or containing products of macrophages. Recombinant IL-1Ra (anakinra) has been administered to over 1,000 patients with septic shock resulting in a consistent reduction in all-cause 28-day mortality. Approved for treatment of rheumatoid arthritis, anakinra has a remarkable safety record. Anakinra resulted in decreased blood vessels in the pannus of affected joints in patients with rheumatoid arthritis. Neutralizing monoclonal antibodies to IL-1beta and a soluble receptor to IL-1 are approved for treating chronic inflammatory diseases. Given the availability of three therapeutic agents for limiting IL-1 activity, the safety of blocking IL-1, and the clear benefit of blocking IL-1 activity in animal models of metastasis and angiogenesis, clinical trials of IL-1 blockade should be initiated, particularly as an add-on therapy of patients receiving antiangiogenesis-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 1×
“[24] In late-stage human melanoma cells, spontaneous secretion active IL-1β is observed via constitutive activation of the NLRP3 inflammasome.”
BackgroundSelf-citationInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease
Masters, S. L., Simon, A., Aksentijevich, I., & Kastner, D. L. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141627 · Cited by 1,065
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
Self-citationAn Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 749
A pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727
(2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00347-3 · Cited by 705
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., & Voronov, E. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9004-4 · Cited by 593
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors
Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200207000-00010 · Cited by 540
Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D., Kivitz, A. J., Silver, D., & Appleton, B. E. (2009) · Arthritis Care & Research · doi:10.1002/art.24096 · Cited by 533
Lewis, A. M., Varghese, S., Xu, H., & Alexander, H. R. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-48 · Cited by 443
Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
Self-citationAn Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus
Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J., & Verbsky, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809568 · Cited by 411
Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 350
Self-citationCytokines as a key component of cancer-related inflammation
Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 331
Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., Voronov, E., Martin, M. U., Dinarello, C. A., & Apte, R. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915018107 · Cited by 329
Self-citationIncreased secretion and expression of myostatin in skeletal muscle from extremely obese women
Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., & Houmard, J. A. (2009) · Diabetes · doi:10.2337/db08-0943 · Cited by 324
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.
Gabay, C., Smith, M. F., Eidlen, D., & Arend, W. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119488 · Cited by 319
Arterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene
Nicklin, M. J. H., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.303 · Cited by 317
Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis
Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R. (2004) · Cancer · doi:10.1002/cncr.20672 · Cited by 315
Inflammation by remote control
Mantovani, A. (2005) · Nature · doi:10.1038/435752a · Cited by 313
Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., Buoncompagni, A., Plebani, A., Merlini, G., & Martini, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23475 · Cited by 312
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Production of interleukin-1-receptor antagonist during experimental endotoxaemia
Granowitz, E. V., Poutsiaka, D. D., Cannon, J. G., Wolff, S. M., Dinarello, C. A., Santos, A. A., & Wilmore, D. W. (1991) · The Lancet · doi:10.1016/0140-6736(91)92725-h · Cited by 310
Self-citationTerkeltaub, R., Sundy, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., Wu, R., Mellis, S., & Radin, A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108936 · Cited by 300
Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., Dinarello, C. A., & Fujita, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064907 · Cited by 293
Self-citationSong, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., & Apte, R. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8200 · Cited by 290
Self-citationThe role of interleukin 1 in growth and metastasis of human cancer xenografts.
Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., & Alexander, H. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1603 · Cited by 288
Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285
Self-citationGattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., D'Osualdo, A., Buoncompagni, A., Alpigiani, M. G., Alessio, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22842 · Cited by 247
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
Brenner, M., Ruzicka, T., Plewig, G., Thomas, P., & Herzer, P. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09404.x · Cited by 225
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis
Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M. A., Fogel, M., Huszar, M., White, M. R., Dinarello, C. A., & Apte, R. N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901511 · Cited by 224 · cited 1×
“[31] When explanted, the matrigel plugs contained 85% less VEGF.”
BackgroundSelf-citationOverproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome
Gherardi, R., Belec, L., Soubrier, M., Malapert, D., Zuber, M., Viard, J., Intrator, L., Degos, J., & Authier, F. (1996) · Blood · doi:10.1182/blood.v87.4.1458.bloodjournal8741458 · Cited by 221
Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease
Fischer, E., Van Zee, K., Marano, M., Rock, C., Kenney, J., Poutsiaka, D., Dinarello, C., Lowry, S., & Moldawer, L. (1992) · Blood · doi:10.1182/blood.v79.9.2196.2196 · Cited by 218
Self-citationCorrection: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer
El-Omar, E. M., Carrington, M., Chow, W.-H., McColl, K. E. L., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C.-C., Rothman, N., et al. (2001) · Nature · doi:10.1038/35083631 · Cited by 217
Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice.
Giavazzi, R., Garofalo, A., Bani, M. R., Abbate, M., Ghezzi, P., Boraschi, D., Mantovani, A., & Dejana, E. (1990) · PubMed · Cited by 201
Khatib, A., Kontogiannea, M., Fallavollita, L., Jamison, B. M., Meterissian, S. H., & Brodt, P. (1999) · PubMed · Cited by 192
Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness
Song, X., Voronov, E., Dvorkin, T., Fima, E., Cagnano, E., Benharroch, D., Shendler, Y., Bjorkdahl, O., Segal, S., Dinarello, C. A., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6448 · Cited by 169
Self-citationBodar, E. J., van der Hilst, J. C. H., Drenth, J. P. H., van der Meer, J. W. M., & Simon, A. (2005) · PubMed · Cited by 166
Beneficial response to interleukin 1 receptor antagonist in traps
Simon, A., Bodar, E. J., van der Hilst, J. C. H., van der Meer, J. W. M., Fiselier, T. J. W., Cuppen, M. P. J. M., & Drenth, J. P. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.039 · Cited by 164
Ferretti, M., Casini–Raggi, V., Pizarro, T. T., Eisenberg, S. P., Nast, C. C., & Cominelli, F. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117345 · Cited by 154
Interleukin 1 Polymorphisms, Lifestyle Factors, and Helicobacter pylori Infection
Hamajima, N., Matsuo, K., Saito, T., Tajima, K., Okuma, K., Yamao, K., & Tominaga, S. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01106.x · Cited by 147
A case of macrophage activation syndrome successfully treated with anakinra
Kelly, A., & Ramanan, A. V. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0919 · Cited by 147
Vidal‐Vanaclocha, F., Amezaga, C. A. V.-D., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994) · PubMed · Cited by 146
Self-citationManagement of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra
McGonagle, D. G., Tan, A. L., Shankaranarayana, S., Madden, J. M., Emery, P., & McDermott, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.073759 · Cited by 146
Mokart, D., Capo, C., Blache, J., Delpéro, J., Houvenaeghel, G. F., Martin, C. M. P., & Mege, J. L. (2002) · British journal of surgery · doi:10.1046/j.1365-2168.2002.02218.x · Cited by 140
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome
de Koning, H. D., Bodar, E. J., Simon, A., van der Hilst, J. C. H., Netea, M. G., & van der Meer, J. W. M. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045245 · Cited by 138
Resistant Behçet Disease Responsive to Anakinra
Botsios, C., Sfriso, P., Furlan, A., Punzi, L., & Dinarello, C. A. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-4-200808190-00018 · Cited by 131
Self-citationRambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A., Dinarello, C., & Cozzolino, F. (1991) · Blood · doi:10.1182/blood.v78.12.3248.3248 · Cited by 129
Self-citationGarofalo, A., Chirivi, R. G. S., Foglieni, C., Pigott, R., Mortarini, R., Martín-Padura, I., Anichini, A., Gearing, A. J. H., Sánchez‐Madrid, F., & Dejana, E. (1995) · PubMed · Cited by 124
Rutkowski, P. L., Kaminska, J. A., Kowalska, M. M., Ruka, W., & Steffen, J. A. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10305 · Cited by 120
Vidal‐Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., & Dinarello, C. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.198 · Cited by 117
Self-citationTargeting Myelomonocytic Cells to Revert Inflammation-Dependent Cancer Promotion
Colombo, M. P., & Mantovani, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2714 · Cited by 113
Cailliez, M., Garaix, F., Rousset‐Rouvière, C., Bruno, D., Koné‐Paut, I., Sarles, J., Chabrol, B., & Tsimaratos, M. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0408-7 · Cited by 112
Dossus, L., Becker, S., Achaintre, D., Kaaks, R., & Rinaldi, S. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.09.001 · Cited by 103
Chang, Y., Jang, J. Y., Kim, N., Lee, J. W., Lee, H., Jung, W. W., Dong, S. H., Kim, H. J., Kim, B., Lee, J. I., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20724 · Cited by 101
Bar, D., Apte, R. N., Voronov, E., Dinarello, C. A., & Cohen, S. (2003) · The FASEB Journal · doi:10.1096/fj.03-0483fje · Cited by 98
Self-citationCoxon, A., Bolon, B. N., Estrada, J., Kaufman, S., Scully, S. A., Rattan, A., Duryea, D., Hu, Y., Rex, K. L., Pacheco, E., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10546 · Cited by 97
Scherbarth, S., & Orr, F. W. (1997) · PubMed · Cited by 94
Cytokine deregulation in cancer
Kurzrock, R. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00140-8 · Cited by 94
Orre, I. J., Murison, R. C. C., Dahl, A. A., Ueland, T., Aukrust, P., & Fosså, S. D. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.04.003 · Cited by 94
Martín-Padura, I., Mortarini, R., Lauri, D., et al. (1991) · PubMed · Cited by 93
Rafiq, S., Stevens, K., Hurst, A. J., Murray, A., Henley, W., Weedon, M. N., Bandinelli, S., Corsi, A. M., Guralnik, J. M., Ferruci, L., et al. (2007) · Genes & Immunity · doi:10.1038/sj.gene.6364393 · Cited by 92
Atkins, M. B., Vachino, G., Tilg, H., et al. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1802 · Cited by 92
THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA
Lust, J. A., & Donovan, K. A. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70115-5 · Cited by 85
Estrov, Z., Kurzrock, R., Estey, E. H., Wetzler, M., Ferrajoli, A., Harris, D., Blake, M. E., Gutterman, J., & Talpaz, M. (1992) · Blood · doi:10.1182/blood.v79.8.1938.1938 · Cited by 76
Schnitzler syndrome: Treatment failure to rituximab but response to anakinra
Eiling, E., Möller, M., Kreiselmaier, I., Brasch, J., & Schwarz, T. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.03.036 · Cited by 75
Chirivi, R. G. S., Garofalo, A., Padura, I. M., Mantovani, A., & Giavazzi, R. (1993) · PubMed · Cited by 75
Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.
Mitroulis, I., Papadopoulos, V. P., Konstantinidis, T. G., & Ritis, K. (2008) · PubMed · Cited by 66
Lauri, D., Bertomeu, M. C., Orr, F. W., Bastida, E., Sauder, D. N., & Buchanan, M. R. (1990) · Clinical & Experimental Metastasis · doi:10.1007/bf00155590 · Cited by 61
Case of anakinra as a steroid‐sparing agent for gout inflammation
Gratton, S. B., Scalapino, K. J., & Fye, K. H. (2009) · Arthritis Care & Research · doi:10.1002/art.24694 · Cited by 60
Lamacchia, C., Palmer, G., Seemayer, C. A., Talabot‐Ayer, D., & Gabay, C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27235 · Cited by 58
H. Ito, C. M. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750024959 · Cited by 56
Graziano, F., Ruzzo, A., Santini, D., Humar, B., Tonini, G., Catalano, V., Berardi, R., Pizzagalli, F., Arduini, F., Bearzi, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.345 · Cited by 56
Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)
Ohlsson, V., Baildam, E. M., Foster, H., Jandial, S., Pain, C. E., Strike, H., & Ramanan, A. V. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/ken030 · Cited by 55
Systemic immune dysfunction in pancreatic cancer patients
Poch, B., Lotspeich, E., Ramadani, M., Gansauge, S., Beger, H. G., & Gansauge, F. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-006-0140-7 · Cited by 53
Furlan, A., Botsios, C., Ruffatti, A., TODESCO, S., & Punzi, L. (2008) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.07.010 · Cited by 53
Intravitreal Anakinra Inhibits Choroidal Neovascular Membrane Growth in a Rat Model
Olson, J. L., Courtney, R. J., Rouhani, B., Mandava, N., & Dinarello, C. A. (2009) · Ocular Immunology and Inflammation · doi:10.1080/09273940802710705 · Cited by 53
Self-citationBodar, E. J., Simon, A., de Visser, M., & van der Meer, J. W. M. (2009) · PubMed · Cited by 51
Torcia, M. G., Lucibello, M., Vannier, E. G., et al. (1996) · PubMed · Cited by 48
Weinreich, D. M., Elaraj, D. M., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., Spiess, P. J., & Alexander, H. R. (2003) · PubMed · Cited by 48
Hu, Z., Shao, M., Chen, Y., Zhou, J.-N., Qian, J., Xu, L., Ma, H., Wang, X., Xu, Y., Li, J., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.015 · Cited by 45
Mechanisms involved in metastasis enhanced by inflammatory mediators
Männel, D. N., Orosz, P., Hafner, M., & Falk, W. (1994) · PubMed · doi:10.5283/epub.16501 · Cited by 41
Chirivi, R. G. S., Chiodoni, C., Musiani, P., Garofalo, A., Bernasconi, S., Colombo, M. P., & Giavazzi, R. (1996) · International Journal of Cancer · Cited by 40
Effect of IL‐1 on experimental bone/bone‐marrow metastases
Arguello, F., Baggs, R. B., Graves, B. T., Harwell, S. E., Cohen, H. J., & Frantz, C. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520522 · Cited by 40
IL-1 Inhibition With Anakinra in a Patient With Refractory Gout
Singh, D., & Huston, K. K. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181be2423 · Cited by 39
Botsios, C., Sfriso, P., Punzi, L., & TODESCO, S. (2007) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740600938647 · Cited by 37
Tao, M., Li, Y., Nayini, J., Andrews, C., Huang, R., Devemy, E., Song, S., Venugopal, P., & Preisler, H. D. (2000) · Cytokine · doi:10.1006/cyto.2000.0666 · Cited by 35
Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer
Parekh, D. J., Ankerst, D. P., Baillargeon, J., Higgins, B., Platz, E. A., Troyer, D. A., Hernández, J., Leach, R. J., Lokshin, A. E., & Thompson, I. M. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0302 · Cited by 34
Graziano, F., Ruzzo, A., Canestrari, E., Loupakis, F., Santini, D., Rulli, E., Humar, B., Galluccio, N., Bisonni, R., Floriani, I., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.16 · Cited by 31
Zöller, M., Douvdevani, A., Segal, S., & Apte, R. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500321 · Cited by 29
Chauffier, K., London, J., Beaudouin, C., & Fautrel, B. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.01.012 · Cited by 24
Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients
Niedżwiecki, S., Stępień, T., Kuzdak, K., Stepien, H., Krupiński, R., Seehofer, D., Rayes, N., & Ulrich, F. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0251-9 · Cited by 22
Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer.
Kopp, W. C., Urba, W. J., Rager, H., Alvord, W. G., Oppenheim, J. J., Smith, J. W., & Longo, D. L. (1996) · PubMed · Cited by 20
Mirkinson, L. J., Nagle, D., Jones, O. Y., & Kadom, N. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000208650.99508.4e · Cited by 19
Bruserud, Ø., Aasen, I., Akselsen, P. E., Bergheim, J., Rasmussen, G., & Nesthus, I. (1996) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1996.tb00495.x · Cited by 13
Cited by
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Self-citationRidker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,104
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Metadata
- Authors
- Dinarello, C. A.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2010-04-28
- Volume
- 29
- Issue
- 2
- Pages
- 317-329
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2004447523
- Cited by
- 277
- References
- 108
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.